While bortezomib inhibited NFκB p65 and BCL-xL 40% in RPMI 8226 MM cells cultured alone, MM cells co-cultured with overweight or obese adipocytes and treated with bortezomib displayed no reduction in these survival factors. Here, BCL2L1 is linked to Miyoshi myopathy.